Protalix BioTherapeutics Inc. has released a corporate presentation detailing its ongoing developments in rare disease treatments. The company highlighted its two partnered commercial enzyme replacement therapies: Elfabrio, approved in the United States, European Union, and other markets in partnership with Chiesi Global Rare Diseases, and Elelyso, approved in 23 markets through a collaboration with Pfizer and Fiocruz in Brazil. The presentation also outlined the progress of PRX-115, a potential best-in-class therapy for uncontrolled gout, currently enrolling patients in a Phase 2 clinical trial. Protalix emphasized its proprietary ProCellEx® platform for plant cell-based protein expression and discussed future pipeline goals targeting rare diseases with a focus on renal indications. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.